Stock ZLAB N ZAI LAB LIMITED
Add to a list

Zai Lab Limited Stock Mexican S.E.

Stocks

ZLAB N

US98887Q1040

Pharmaceuticals

OTC Markets Traded
End-of-day quote Mexican S.E.
Other stock markets
 2025-06-12 		5-day change 1st Jan Change
810.00 MXN +43.36% Intraday chart for Zai Lab Limited -.--% -
Jun. 29 Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing MT
Jun. 16 Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug MT

Valuation: Zai Lab Limited

Market Cap 2.3B 40.33B 2.02B 1.88B 1.72B 3.26B 220B 3.33B 22.36B 8.75B 108B 8.64B 8.46B 374B P/E 2026 *
-9.25x
P/E 2027 * -11x
Enterprise Value 1.86B 32.57B 1.63B 1.51B 1.39B 2.63B 178B 2.69B 18.06B 7.06B 87.33B 6.98B 6.83B 302B EV / Sales 2026 *
4.14x
EV / Sales 2027 * 3.22x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
* Estimated data More valuation ratios

Latest news : Zai Lab Limited

Jun. 29 Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing MT
Jun. 16 Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug MT
Jun. 10 Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading MT
Jun. 09 China Approves Pfizer's Tivdak for Cervical Cancer Treatment Zonebourse
Jun. 09 Zai Lab Says China Approves Tivdak for Cervical Cancer Treatment MT
Jun. 09 Zai Lab Receives China NMPA Approval For TIVDAK For Treatment Of Recurrent Or Metastatic Cervical Cancer CI
May. 29 Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up for Week MT
May. 22 Zai Lab President, COO Josh Smiley to Depart MT
May. 21 Zai Lab Ousts COO Josh Smiley MT
May. 21 Zai Lab Limited Announces Departure of Josh Smiley as President and COO, Effective May 22, 2026 CI
May. 19 Zai Lab Insider Sold Shares Worth $1,986,875, According to a Recent SEC Filing MT
May. 18 Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Trading MT
May. 15 Zai Lab Insider Sold Shares Worth $2,003,044, According to a Recent SEC Filing MT
More news

Last Transcript: Zai Lab Limited

Logo Zai Lab Limited
Zai Lab Limited, Q1 2026 Earnings Call, May 07, 2026
May. 07
More transcripts

Analysts' recommendations: Zai Lab Limited

Jan. 07 UBS Initiates Zai Lab at Buy With $35 Price Target MT
Nov. 04 Zai Lab updates on Amgen's bemarituzumab Phase 1B/3 Fortitude-102 study RE
Nov. 04 Zai Lab Limited Announces Update on Amgen's Bemarituzumab Phase 1B/3 Fortuda-102 Study CI
25-03-13 JPMorgan Adjusts Price Target on Zai Lab to $51 From $44, Keeps Overweight Rating MT
25-03-03 BofA Securities Downgrades Zai Lab to Neutral MT
More recommendations

Press Releases: Zai Lab Limited

Jun. 17 Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan in Pulmonary Neuroendocrine Carcinomas AQ
Jun. 16 Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas BU
Jun. 08 Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer BU
May. 21 Zai Lab Announces Changes to Senior Leadership Team BU
May. 11 Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) BU
More press releases

News in other languages: Zai Lab Limited

Jun. 09 La Chine approuve le Tivdak de Pfizer dans le cancer du col de l'utérus
22-10-19 Hong Kong se convierte en el principal mercado para las cotizaciones chinas, según HKEX -- Market Talk
22-07-28 Tweede kwartaal Argen-x in teken lancering Vyvgart
22-05-05 Brussel fors hoger van start na Fed-rally op Wall Street
22-05-05 Argenx boekt eerste omzet met Vyvgart
More news

Course Extremes

3 years 270.64
Extreme 270.64
 810
5 years 270.64
Extreme 270.64
 2,446.85
10 years 270.64
Extreme 270.64
 3,693.35
More quotes

Managers and Directors: Zai Lab Limited

Manager TitleAgeSince
Ying Du CEO
 Chief Executive Officer 61 2014-03-31
Ya jing Chen DFI
 Director of Finance/CFO 58 2023-07-06
Rafael Amado PSD
 President 62 2022-11-30
Director TitleAgeSince
Ying Du CHM
 Chairman 61 2014-03-31
John Diekman BRD
 Director/Board Member 83 2016-12-31
Peter Wirth BRD
 Director/Board Member 75 2016-12-31
More insiders

Biopharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
ZAI LAB LIMITED Stock Zai Lab Limited
+43.36%-.--% - - 2.3B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
-0.22%+1.35%+16.79%-7.70% 67.61B
UCB Stock UCB
-0.63%-9.21%+37.82%+200.20% 51.6B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+0.36%+40.00%+40.00%+40.00% 43B
CSL LIMITED Stock CSL Limited
-1.26%-0.39%-49.63%-53.84% 40.94B
BIOGEN INC. Stock Biogen Inc.
+4.96%-3.28%+55.75%-24.71% 29.4B
MODERNA, INC. Stock Moderna, Inc.
-1.85%-15.99%+99.20%-46.78% 27.09B
INCYTE CORPORATION Stock Incyte Corporation
-2.12%-2.25%+66.54%+82.33% 23.32B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-0.67%+1.48%+10.61%+188.35% 19.92B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-2.12%-3.72%+61.37%+126.08% 16.91B
Average +3.80%-3.29%+37.61%+55.99% 35.53B
Weighted average by Cap. -0.15%-3.06%+30.96%+47.33%
See all sector performances

Financials

2026 *2027 *
Net sales 449M 7.86B 394M 366M 336M 635M 42.9B 649M 4.36B 1.7B 21.08B 1.68B 1.65B 72.88B 596M 10.43B 523M 485M 446M 843M 56.95B 861M 5.78B 2.26B 27.98B 2.24B 2.19B 96.73B
Net income -241M -4.22B -212M -196M -180M -341M -23.03B -348M -2.34B -915M -11.32B -905M -885M -39.13B -156M -2.74B -137M -127M -117M -221M -14.96B -226M -1.52B -594M -7.35B -588M -575M -25.41B
Net Debt -443M -7.76B -389M -361M -332M -627M -42.37B -641M -4.3B -1.68B -20.82B -1.66B -1.63B -71.97B -387M -6.78B -340M -315M -290M -548M -37.02B -560M -3.76B -1.47B -18.19B -1.45B -1.42B -62.89B
* Estimated data More financial data

Company Profile

Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Sector
Pharmaceuticals
More about the company

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

-
Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

-
Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
20.49USD
Average target price
33.30USD
Spread / Average Target
+62.53%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Stocks
  3. ZLAB Stock
  4. ZLAB N Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong